INDO-BANGLA PHARMACEUTICALS LIMITED

PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD,
BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals Limited ("Company") in its meeting held on **Wednesday 30th April, 2025 at 4:00 p.m.** at the corporate office, has approved the Un-Audited Financial Statements for the Third Quarter (Q3) period ended on 31th March, 2025.

The key financial highlights for the Third Quarter ended 31th March, 2025 are appended below:

SL No.	Particulars	9 months		3 months	
		July to March		January to March	
		2024-2025	2023-2024	2024-2025	2023-2024
1.	Earnings Per Share (EPS)	(0.17)	(0.13)	(0.09)	(0.08)
2.	Net Operating Cash Flows Per Share (NOCFPS)	0.02	0.19	-	-
		As at 31st March, 2025		As at 30th June, 2024	
3.	Net Asset Value (NAV) per share	13.43		13.60	

The reasons, for significant deviation:

- During the period from 1st July, 2024 to 31 March, 2025 sales revenue has decreased by 52.66% from BDT 162,460,031 to BDT 76,915,773 in comparison to the same period of the previous year due to limitation of opening L/C to import raw materials which hampered our production as well as sales.
- **Earnings per Share (EPS)** has been decreased compared to the same period of the previous year due to decreased in sales revenue.
- **NOCFPS** has been decreased due to decrease in supplier's payment during the reporting period.
- **NAVPS** has also been decreased due to net loss after tax.

By order of the Board of Directors

-sd-

(Mohi Uddin)
Company Secretary

The details of the published Third Quarter (Q3) Financial Statements are available in the website of the company: **www.indo-banglapharma.com.**